Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk

Dow Jones

01/23

0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com)

(END) Dow Jones Newswires

January 22, 2026 21:11 ET (02:11 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2605413442"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605413442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605413442?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605413442","market":"us","top_or_hot":-1,"title":"Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 21:11 ET (02:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-23 10:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 21:11 ET (02:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSL.SI","symbol_name":"莱佛士医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2605413442","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605413442","pubTimestamp":1769134260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BSL.SI":"莱佛士医疗"},"translate_title":"莱佛士医疗可能在2026-2027年维持盈利势头——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSL.SI":1.5},"content_text":"0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2026 21:11 ET (02:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}